Skip to main content
Sign In

Welcome to the Barbara Davis Center for Diabetes at the University of Colorado School of Medicine on the Anschutz Medical Campus in Aurora, Colorado.

Barbara Davis Center Banner Image
 

Effects of GAD on the Progression of Type 1 Diabetes in New Onset Subjects

The GAD65 Research Study


 

Principal Investigator: Peter Gottlieb, COMIRB #: 08-1338 Version: 12/01/08

The GAD65 Research Study is looking for people newly diagnosed with type 1 diabetes. The goal of this study is to learn if a vaccine, GAD-alum, could help people with newly diagnosed type 1 diabetes by delaying or stopping the further destruction of beta cells.

Why should you consider this study?

  • You will be part of a research study to see if we can stop or slow down your  body’s attack on the cells that produce insulin.
  • If the proposed treatment is successful, you may have an easier time managing your diabetes.
  • The information from this study may help other people with diabetes.

Who can sign up for this study?

  • People who have been diagnosed with Type 1 Diabetes within the past 3 months.
  • Age 3-45 years old. *
  • Presence of GAD65 antibody.

*Age staggered enrollment

What will happen in this study?

  • You will be assessed for general health and diabetes care.
  • If you qualify, you will be assigned to one of three study groups: 3 injections of GAD-Alum, or 2 injections GAD-Alum and 1 injection placebo, or 3 injections placebo.
  • You will be monitored for 2-4 years for assessment of beta cell function and diabetes care outcomes.

Who should I call with questions or to schedule an appointment?

Lisa Meyers: 303-724-6893 or Lisa.Meyers@ucdenver.edu
Sandy Barry: 303-724-7501 or Sandra.Barry@ucdenver.edu

http://www.clinicaltrials.gov